RESUMO
Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripheral blood and lymphoid organs. CDX-301 has an identical amino-acid sequence and comparable biological activity to the previously tested rhuFlt3L, which ceased clinical development over a decade ago. This Phase 1 trial assessed the safety, pharmacokinetic, pharmacodynamic and immunologic profile of CDX-301, explored alternate dosing regimens and examined the impact of rhuFlt3L on key immune cell subsets. Thirty healthy volunteers received CDX-301 (1-75 µg/kg/day) over 5-10 days. One event of Grade 3 community-acquired pneumonia occurred. There were no other infections, dose-limiting toxicities or serious adverse events. CDX-301 resulted in effective peripheral expansion of monocytes, hematopoietic stem and progenitor cells and key subsets of myeloid DCs and plasmacytoid DCs, with no clear effect on regulatory T cells. These data from healthy volunteers support the potential for CDX-301, as monotherapy or in combination with other agents, in various indications including allogeneic HSC transplantation and immunotherapy, but the effects of CDX-301 will need to be investigated in each of these patient populations.
Assuntos
Células Dendríticas/imunologia , Transplante de Células-Tronco Hematopoéticas/métodos , Condicionamento Pré-Transplante/métodos , Tirosina Quinase 3 Semelhante a fms/genética , Tirosina Quinase 3 Semelhante a fms/metabolismo , Adolescente , Adulto , Feminino , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Adulto JovemRESUMO
This evaluation compared the pressure support qualities of three mattresses by measuring the interface pressures using 20 subjects. The results indicate that the Pegasus Airwave mattress had significantly higher readings than Quattro DC2000 (p = 0.021, 95% confidence level) and the Nimbus II (p = 0.009, 99% confidence level) but that there is no significant difference between interface pressures for the Quattro DC2000 and the Nimbus II.
Assuntos
Leitos/normas , Úlcera por Pressão/prevenção & controle , Leitos/provisão & distribuição , Estudos de Avaliação como Assunto , Humanos , PressãoRESUMO
In this study, three mattresses were evaluated to assess their effectiveness in relation to the pain and discomfort experienced by 40 patients with neurological disorders who had Waterlow scores > or = 15 and required pressure support. The results indicate that one mattress (the Quattro DC2000) performed significantly better than the other two (Nimbus II and Pegasus Airwave).
Assuntos
Leitos/normas , Doenças do Sistema Nervoso/complicações , Dor/etiologia , Dor/prevenção & controle , Adolescente , Adulto , Leitos/provisão & distribuição , Estudos de Avaliação como Assunto , Humanos , Pessoa de Meia-Idade , Dor/psicologia , Medição da Dor , Satisfação do Paciente , Pressão , Inquéritos e QuestionáriosRESUMO
ALTERNATING-PRESSURE MATTRESS REPLACEMENTS.
Assuntos
Glicoproteínas/química , Estrutura Secundária de Proteína , Ativador de Plasminogênio Tecidual/química , Ativador de Plasminogênio Tecidual/metabolismo , Animais , Células CHO , Dicroísmo Circular , Cricetinae , Estabilidade Enzimática , Glicoproteínas/metabolismo , Humanos , Desnaturação Proteica , Proteínas Recombinantes/química , Proteínas Recombinantes/metabolismo , TransfecçãoRESUMO
The earliest tissue plasminogen activator (t-PA) preparations prepared from melanoma cells were expressed in urinary-type plasminogen activator (u-PA) units of activity using the u-PA International Standard (66/46). This report describes a comparison between u-PA and t-PA units by various types of fibrin plate procedure using both human and bovine fibrin. Within the biometric limits of this procedure it was found that the potency ratio of u-PA/t-PA was 3.5 (human fibrin), 5.29 (enriched bovine fibrin) and 4.6 (crude bovine fibrin). Specific activity figures of approximately 100,000 IU/mg for pure t-PA using the urokinase standard (66/46) would convert to approximately 350,000-530,000 IU/mg using the International Standards for t-PA (83/517 and 87/670). This latter figure is compatible with the reported specific activity for purified preparations of recombinant t-PA.